1. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.
- Author
-
KUWAYAMA, H., ASAKA, M., SUGIYAMA, T., FUKUDA, Y., AOYAMA, N., HIRAI, Y., and FUJIOKA, T.
- Subjects
TREATMENT of helicobacter pylori infections ,HELICOBACTER pylori ,ANTIBIOTICS ,PROTON pump inhibitors - Abstract
Background Large-scale studies of rabeprazole-based Helicobacter pylori eradication therapy have not been reported in Japan. Aims To evaluate H. pylori eradication by rabeprazole-based therapy with reference to antibiotic susceptibility, CYP2C19 genotype, and rabeprazole and clarithromycin dosages. Methods From 35 centres 479 H. pylori-positive patients with gastric or duodenal ulcer were randomized to four treatment groups: Group 1 (10 mg rabeprazole + 750 mg amoxicillin + 200 mg clarithromycin twice daily for 7 days); Group 2 (10 mg, 750 mg, 400 mg); Group 3 (20 mg, 750 mg, 200 mg) and Group 4 (20 mg, 750 mg, 400 mg). Results Eradication rates were 86% (102 of 119), 89% (97 of 109), 91% (106 of 116) and 90% (104 of 115) for Groups 1–4, respectively. The eradication rate was 95% (360 of 379) for clarithromycin-susceptible strains, and 50% (30 of 60) for clarithromycin-resistant strains. The eradication rates were 88% (332 of 379) and 96% (77 of 80) in extensive metabolizers and poor metabolizers, respectively. Conclusions Rabeprazole-based therapies achieved 50% eradication of clarithromycin-resistant H. pylori, and even achieved good rates in extensive metabolizers. Accordingly, rabeprazole can be recommended as part of a first-line proton pump inhibitor-based triple therapy for H. pylori. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF